To use all functions of this page, please activate cookies in your browser.
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Anti-idiotypic vaccines comprise antibodies that have three-dimensional immunogenic regions, designated idiotopes, that consist of protein sequences that bind to cell receptors. Idiotopes are aggregated into idiotypes specific of their target antigen.
Additional recommended knowledge
Production and use
In one example of producing an anti-idiotypic vaccine, antibodies that bind tumor-associated antigens (TAA) are isolated and injected into mice. To the murine immune system, the TAA antibodies are antigens and cause an immunogenic reaction producing murine antibodies that can bind to the "TAA idiotype" and is said to be "anti-idiotypic". The resulting murine antibodies are harvested and used to vaccinate other mice. The resulting antibodies in the second set of mice have a three-dimensional binding site that mimics the structure, i. e., idiotopes, of the original TAA, i.e., they present the idiotype of the TAA. These antibodies are combined with an adjuvant and given as a vaccine. The murine immune system essentially "amplifies" a small mass of TAA antibodies into a much larger mass used to vaccinate humans. Because the antibody produced using the "anti-idiotypic" process closely resembles the antigen, these antibodies can be used to induce immune responses from cellular to antibody-antigen for a given antigen, e. g., TAA, when administered as a vaccine to a human. They are mainly used for high risk cancer patients.
|This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Anti-idiotypic". A list of authors is available in Wikipedia.|